Emyria Ltd · ASX:EMD
Emyria — Emerald Clinics — Investor Presentation (June 2020)
25 slides from Emyria's investor presentation, Jun 25, 2020
Slide 1: Company Update – June 2020
For personal use only emerald Evidence Generating Care www.emeraldclinics.com.au Company Update – June 2020 Michael Winlo – MD & CEO
Slide 2: Disclaimer and notices
Disclaimer and notices For personal use only This presentation has been prepared by Emerald Clinics Limited ACN 625 085 734 (Company or Emerald). This presentation is not a financial product or investment advice or recommendation, offer or invitation by any person or to any person to sell or purchas
Slide 3: Emerald | Real-world clinical evidence
Emerald | Real-world clinical evidence For personal use only Emerald is a team of medical doctors, clinical researchers and data scientists. We provide data-driven patient care across our network of clinics. We develop digital health technologies that help generate accurate and actionable clinical e
Slide 4: Funding History & Focus
Funding History & Focus emd For personal use only u Listed on the ASX, 12 February 2020 (ticker: EMD) u IPO funding $6m | Last reported cash position (Q1, 2020): $5.018M | Market cap: $9.38M (24 Jun 2020) u Milestones since listing: u 1000 + patients to 6 months, commercialised data, completed trial
Slide 5: Investment highlights
Investment highlights emd For personal use only Strong patient and referrer demand Experienced clinical team delivering a Patient-centric, telehealth-supported unique care model Robust, ethically captured clinical evidence Unique treatment insights (what works?, for who?) How we create and capture v
Slide 6: Experienced board with medical focus
Experienced board with medical focus emd For personal use only Key Role Previous Experience Person 30 years of CEO and Board experience in medical and agrifood biotech companies. Chairman of Orthocell Ltd (ASX:OCC), regenerative medicine company, Founding Chairman and current Director of Cynata Ther
Slide 7: Real-world evidence (RWE)
For personal use only Real-world evidence (RWE): Emerald’s model generates valuable clinical evidence during clinical care
Slide 8: Sources of clinical evidence
Sources of clinical evidence emd For personal use only High data quality Emerald real- Clinical trial data world evidence Low external validity High external validity 3rd party data (eg, claims data) Clinical service data Low data quality
Slide 9: RWE can shorten treatment development times & costs
RWE can shorten treatment development times & costs emd For personal use only
Slide 10: Emerald’s Real World Evidence (RWE) care model
Emerald’s Real World Evidence (RWE) care model emd For personal use only u 16 GPs and Specialists (all GCP-trained) u Proprietary data model and system u In-house data management, integration & analysis u 4 locations around Australia
Slide 11: Emerald revenue streams
Emerald revenue streams emd For personal use only Clinical care 2 Clinical trials 1 (patients & health insurers) MAJOR FOCUS: 3 Consulting services 4 RWE insights
Slide 12: Development pipeline
For personal use only Development pipeline Emerald develops digital health tools that support RWE generation
Slide 13: Overview of Emerald’s RWE engine
Overview of Emerald’s RWE engine emd For personal use only Data Capture Patient Management Programs Data Management & Analysis Clinical 3rd party Chronic Remote assessment clinical Medicinal COVID 19 disease/at Medrio Clinical vital signs & on patients Patient databases cannabis safe “back risk Clin
Slide 14: Emerald’s RWE architecture
Emerald’s RWE architecture emd For personal use only Data Capture Patient Management Data Analysis Real-world outcome data informs ongoing algorithm development, research and clinical trials
Slide 15: Emerald’s RWE programs
Emerald’s RWE programs emd For personal use only Today: EMD Cannabinoid Management Clinical Services In development now: *COVID-19 Monitoring EMD Data Potential: Services Complex diseases where evidence is lacking *For further details, please see ASX Announcement of 22 June 2020
Slide 16: Real-world evidence for cannabinoid-based medicines (CBMs)
For personal use only Real-world evidence for cannabinoid-based medicines (CBMs)
Slide 17: Emerald’s cannabinoid medicine RWE asset
Emerald’s cannabinoid medicine RWE asset emd For personal use only u CHALLENGE: u Cannabinoid-based medicines (CMBs) lack high-quality, product-specific, clinical evidence to guide prescribing, registration and payment coverage decisions u APPROACH: u Build and deploy a RWE platform within an indepe
Slide 18: Emerald’s cannabinoid medicine RWE asset
Emerald’s cannabinoid medicine RWE asset emd For personal use only Top indications • Clinical-trial grade data capture 1 Chronic non-cancer pain • Licensed and validated clinical assessments 2 Cancer Pain • We covert all data into standardised models 3 Other Indications 4 Insomnia 5 Neurological Spa
Slide 19: Case Study - Bob
Case Study - Bob emd For personal use only u Vietnam Veteran injured by large tree fall in 1969 causing multiple fractures u Long-standing chronic back pain, developed peripheral neuropathy thought to be due to exposure to Agent Orange with history of PTSD u Under care of pain specialists using oxyc
Slide 20: Clinical growth during COVID-19
Clinical growth during COVID-19 emd For personal use only 700 ~700 Monthly Appointments 654 (forecast) 525 526 528 470 460 Mar 24: Non- 350 essential businesses 341 close Mar 10: Apr 5: WA Australia closes 175 Feb 21: confirms borders WA 100th COVID-19 > confirms case first case 0 Dec-19 Jan-20 Feb-
Slide 21: Fighting COVID-19 with Real-World Evidence
For personal use only Fighting COVID-19 with Real-World Evidence
Slide 22: Why do we need better COVID-19 monitoring?
Why do we need better COVID-19 monitoring? emd For personal use only u COVID-19 is here to stay as a global pandemic u Social distancing may be necessary into 2022 in the US 1 u Development of a vaccine is by no means certain u 100+ vaccine candidates entering trials 2 however, no coronavirus vaccin
Slide 23: The Emerald approach
For personal use only The Emerald approach • A clinician-led monitoring service: • Our extended RWE platform can now help monitor symptoms and vital signs using just a smartphone • Intelligent alerts help identify patients requiring further clinical review by our clinical team • Our team of trained
Slide 24: What’s ahead
What’s ahead emd For personal use only u Cannabinoid medicine RWE: u Ongoing commercialisation of RWE u Clinical trials u Expansion into UK u COVID-19 Opportunities: u Clinical monitoring - COVID-19 Vaccine trial (150 participants, 2 years) u A tool to assist organisations to get “back to business”
Slide 25: Company Contacts
For personal use only emerald Evidence Generating Care www.emeraldclinics.com.au Company Contacts Media Enquires - media@emeraldclinics.com.au Investor Enquires - investors@emeraldclinics.com.au Partnership Enquiries - evidencepartners@emeraldclinics.com.au Patient Enquiries - patients@emeraldclinic